Altimmune (ALT) announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to employ Gregory Weaver as Altimmune’s CFO, effective November 11, 2024. The equity awards were approved on November 6, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Weaver received, in the aggregate, options to purchase 225,000 shares of Altimmune’s common stock, and 75,000 restricted stock units. The options will have an exercise price equal to the closing price of Altimmune’s common stock on November 11, 2024. Based on the closing price Altimmune’s common stock on November 8, 2024, Altimmune would issue approximately 172,920 options as inducement awards under its 2018 Inducement Grant Plan, and the balance as incentive stock options under its 2017 Omnibus Incentive Plan. The final allocation of options between the 2018 Inducement Grant Plan and 2017 Omnibus Plan are subject to adjustment based on the closing price of Altimmune’s common stock on the Grant Date. One-fourth of the shares underlying the options will vest on the one-year anniversary of the Grant Date and thereafter 1/36th of the shares underlying the options will vest monthly, such that the shares underlying the options will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Mr. Weaver’s continued employment with Altimmune on such vesting dates. One-fourth of the RSUs will vest on the one-year anniversary of the Grant Date and thereafter the RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Mr. Weaver’s continued employment with Altimmune on such vesting dates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune appoints Greg Weaver as CFO
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- Altimmune announces successful completion of End-of-Phase 2 meeting
- ALT Upcoming Earnings Report: What to Expect?
- Altimmune call volume above normal and directionally bullish